Patents by Inventor Phillip Frost
Phillip Frost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11712419Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: GrantFiled: December 12, 2019Date of Patent: August 1, 2023Assignee: OPKO Pharmaceuticals, LLCInventors: Arturo Santos, Phillip Frost
-
Publication number: 20230096602Abstract: Methods of treating renal disease or treating at least one of muscle wasting, low muscle strength, or low physical function in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating symptoms as a result of secondary hypogonadism induced by renal replacement therapy or kidney failure in a subject having renal disease by administering at least one tetrahydrocyclopenta[b]indole compound.Type: ApplicationFiled: January 26, 2021Publication date: March 30, 2023Applicant: Eirgen Pharma Ltd.Inventors: Antonio F. CRUZ, Phillip FROST
-
Patent number: 11590148Abstract: Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.Type: GrantFiled: April 3, 2019Date of Patent: February 28, 2023Assignee: EIRGEN PHARMA LTD.Inventors: Charles W. Bishop, Phillip Frost
-
Patent number: 11458199Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: GrantFiled: May 30, 2019Date of Patent: October 4, 2022Assignee: OPKO Pharmaceuticals, LLCInventors: Arturo Santos, Phillip Frost, Jane Hsiao
-
Publication number: 20200163877Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration diabetic macular edema and corneal neovascularization.Type: ApplicationFiled: December 12, 2019Publication date: May 28, 2020Inventors: Arturo SANTOS, Phillip FROST
-
Patent number: 10548841Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: GrantFiled: August 15, 2013Date of Patent: February 4, 2020Assignee: OPKO Pharmaceuticals, LLCInventors: Arturo Santos, Phillip Frost
-
Publication number: 20190321467Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: ApplicationFiled: May 30, 2019Publication date: October 24, 2019Inventors: Arturo SANTOS, Phillip Frost, Jane Hsiao
-
Publication number: 20190298744Abstract: Methods and compositions for treating bariatric surgery patients, and for treating or preventing complications associated with such patients, are disclosed.Type: ApplicationFiled: April 3, 2019Publication date: October 3, 2019Inventors: Charles W. Bishop, Phillip Frost
-
Publication number: 20180185347Abstract: Methods of treating the signs and symptoms of Benign Prostatic Hyperplasia (BPH) in a subject by administering at least one tetrahydrocyclopenta[b]indole compound are disclosed. Also disclosed are methods of treating the signs and symptoms of BPH in a subject by administering at least one tetrahydrocyclopenta[b]indole compound in combination with a phosphodiesterase type-5 inhibitor.Type: ApplicationFiled: November 15, 2017Publication date: July 5, 2018Applicant: Transition Therapeutics (Ireland 2) LimitedInventors: Antonio F. CRUZ, Phillip FROST
-
Publication number: 20180153872Abstract: The invention relates to pharmaceutical compositions and dosage forms having a piperidine carbonitrile as an active ingredient for the treatment of various diseases and conditions. The preferred compound is a crystalline form of a trifluoromethylphenylalkoxyalkylheteroarylaryl piperidine carbonitrile. Methods of treating diseases and conditions are disclosed as well as processes to make crystalline forms of the above compounds.Type: ApplicationFiled: July 12, 2016Publication date: June 7, 2018Inventors: Jane H. HSIAO, Phillip FROST
-
Patent number: 9458199Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the comcomitant removal of T-cells associated with autoimmune disorders.Type: GrantFiled: October 24, 2013Date of Patent: October 4, 2016Assignee: OPKO Pharmaceuticals, LLCInventors: Phillip Frost, Thomas Kodadek
-
Publication number: 20150224055Abstract: The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof Selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.Type: ApplicationFiled: August 15, 2013Publication date: August 13, 2015Inventors: Arturo Santos, Phillip Frost
-
Publication number: 20140147455Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the comcomitant removal of T-cells associated with autoimmune disorders.Type: ApplicationFiled: October 24, 2013Publication date: May 29, 2014Applicant: OPKO Pharmaceuticals, LLCInventors: Phillip FROST, Thomas Kodadek
-
Patent number: 8603756Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.Type: GrantFiled: April 10, 2012Date of Patent: December 10, 2013Assignee: OPKO Pharmaceuticals, LLCInventors: Phillip Frost, Thomas Kodadek
-
Patent number: 8470792Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.Type: GrantFiled: December 4, 2009Date of Patent: June 25, 2013Assignee: Opko Pharmaceuticals, LLC.Inventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
-
Publication number: 20120219574Abstract: The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases. The ligands may be useful as drugs in the treatment of such diseases and can also be used in combination with the concomitant removal of T-cells associated with autoimmune disorders.Type: ApplicationFiled: April 10, 2012Publication date: August 30, 2012Applicant: OPKO Pharmaceuticals, LLCInventors: Phillip FROST, Thomas Kodadek
-
Publication number: 20100151007Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.Type: ApplicationFiled: December 4, 2009Publication date: June 17, 2010Applicant: OPKO OPHTHALMICS, LLCInventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
-
Patent number: 5422125Abstract: A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.Type: GrantFiled: October 12, 1994Date of Patent: June 6, 1995Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Jay S. Skyler, Phillip Frost, Elliot F. Hahn
-
Patent number: 5187163Abstract: Novel anti-viral compounds comprise phosphate-linked dimers of anti-viral nucleoside derivatives, or salts or esters of such nucleoside dimers. Pharmaceutical compositions containing the dimers and methods of treatment utilizing the same are disclosed.Type: GrantFiled: January 28, 1992Date of Patent: February 16, 1993Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Phillip Frost, Jack Fishman, Elliot Hahn, Jing J. Lu
-
Patent number: D439325Type: GrantFiled: February 8, 2000Date of Patent: March 20, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventor: Phillip Frost